Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.39 AUD | +0.13% | +2.33% | +52.68% |
05:34am | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
May. 20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
Sales 2024 * | 744M 495M | Sales 2025 * | 940M 626M | Capitalization | 5.14B 3.42B |
---|---|---|---|---|---|
Net income 2024 * | 50M 33.29M | Net income 2025 * | 104M 69.25M | EV / Sales 2024 * | 6.73 x |
Net cash position 2024 * | 131M 87.18M | Net cash position 2025 * | 200M 133M | EV / Sales 2025 * | 5.25 x |
P/E ratio 2024 * |
98.9
x | P/E ratio 2025 * |
48.2
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.41% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +0.20% | ||
1 week | +2.39% | ||
Current month | +2.33% | ||
1 month | +9.22% | ||
3 months | +40.00% | ||
6 months | +64.53% | ||
Current year | +52.78% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | - | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | - | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | - | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 14 M€ | -2.98% | ||
0.04% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 15.39 | +0.13% | 1 228 344 |
24-05-20 | 15.37 | +3.85% | 1,216,593 |
24-05-17 | 14.8 | -4.21% | 720,019 |
24-05-16 | 15.45 | +2.52% | 640,227 |
24-05-15 | 15.07 | +0.20% | 471,345 |
Delayed Quote Australian S.E., May 21, 2024 at 01:45 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.78% | 3.43B | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.62% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- TLX Stock